Loss of heterozygosity at chromosome 1p in human breast cancer. 1996

G Ragnarsson, and A Sigurdsson, and G Eiriksdottir, and R Barkardottir, and J Jonasson, and S Ingvarsson
UNIV ICELAND,DEPT PATHOL,IS-121 REYKJAVIK,ICELAND. NATL HOSP ICELAND,IS-121 REYKJAVIK,ICELAND.

232 human primary invasive breast tumors were analyzed with 13 polymorphic microsatellite markers specific to chromosome 1p. Loss of heterozygosity (LOH) was observed in 126 cases or 54% of the tumors. One marker, D1S496, at the 1p35 region showed the highest LOH, 28%. High frequencies of LOH were also detected by the markers, D1S488, D1S167 and D1S435, at the 1p31 region, 25%, 24% and 26% LOH, respectively. This suggests the presence of tumor suppressor genes at these two regions. Tumors with and without LOH at 1p were tested for association with clinico-pathological features of the tumors such as estrogen- and progesterone-receptor content (ER and PgR), age at diagnosis, tumor size, node status, histological type, S-phase fraction, ploidy, survival and LOH at chromosomes 3p, 6q, 9p, 11p, 11q, 13q, 16q, 17p and 17q. A significant association was found between LOH at chromosome 1p and high S-phase fraction and lower survival rate. Association was also found between LOH at 1p and chromosome regions 3p, 6q, 9p and 17q. A multivariate model including prognostic variables, showed that LOH at 1p is an independent prognostic variable and patients who have breast tumors with LOH at 1p have approximately a two-fold increase in relative risk of death. We conclude that screening for 1p deletions gives additional prognostic information that might be useful in breast cancer treatment.

UI MeSH Term Description Entries

Related Publications

G Ragnarsson, and A Sigurdsson, and G Eiriksdottir, and R Barkardottir, and J Jonasson, and S Ingvarsson
April 1995, Cancer research,
G Ragnarsson, and A Sigurdsson, and G Eiriksdottir, and R Barkardottir, and J Jonasson, and S Ingvarsson
August 1999, Genes, chromosomes & cancer,
G Ragnarsson, and A Sigurdsson, and G Eiriksdottir, and R Barkardottir, and J Jonasson, and S Ingvarsson
March 1999, British journal of cancer,
G Ragnarsson, and A Sigurdsson, and G Eiriksdottir, and R Barkardottir, and J Jonasson, and S Ingvarsson
October 1995, Cancer research,
G Ragnarsson, and A Sigurdsson, and G Eiriksdottir, and R Barkardottir, and J Jonasson, and S Ingvarsson
October 1997, European journal of cancer (Oxford, England : 1990),
G Ragnarsson, and A Sigurdsson, and G Eiriksdottir, and R Barkardottir, and J Jonasson, and S Ingvarsson
September 1989, Proceedings of the National Academy of Sciences of the United States of America,
G Ragnarsson, and A Sigurdsson, and G Eiriksdottir, and R Barkardottir, and J Jonasson, and S Ingvarsson
August 1995, Genes, chromosomes & cancer,
G Ragnarsson, and A Sigurdsson, and G Eiriksdottir, and R Barkardottir, and J Jonasson, and S Ingvarsson
June 1992, Lancet (London, England),
G Ragnarsson, and A Sigurdsson, and G Eiriksdottir, and R Barkardottir, and J Jonasson, and S Ingvarsson
November 2006, Journal of neuro-oncology,
G Ragnarsson, and A Sigurdsson, and G Eiriksdottir, and R Barkardottir, and J Jonasson, and S Ingvarsson
May 1993, Lancet (London, England),
Copied contents to your clipboard!